Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.
about
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialBasic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapiesThe xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinasePulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Molecular physiopathogenetic mechanisms and development of new potential therapeutic strategies in persistent pulmonary hypertension of the newbornDehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.Update in pulmonary hypertension 2005.The pulmonary circulation in neonatal respiratory failure.Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn.Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.Update on PPHN: mechanisms and treatment.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Stimulators of soluble guanylyl cyclase: future clinical indicationsThe utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia.Redox Mechanisms Influencing cGMP Signaling in Pulmonary Vascular Physiology and Pathophysiology.Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep.Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs.
P2860
Q24656131-C2F8C567-FEBB-496B-9550-BF6538E40123Q33849207-B03DDD0B-5CD1-42DD-B1A7-DEE118B9A8C9Q34112875-5A75C4C9-DAAA-4682-B438-7C08D071EC10Q34212268-282D1C4B-78CE-4CE4-9913-92F1BAC5EDB5Q35010064-E441DC79-F965-4026-902B-F66B3425D8D8Q35084278-3205F096-7DF0-4CBF-8AA7-097940C29110Q35946199-866C52E2-6421-49BF-BFF1-B9F317CCC821Q36403168-0D9C7D13-0605-46F7-98CF-E97E18C90FB4Q36687766-4713C40F-F057-4AFF-A29A-770E8A164801Q36851867-34395DCB-7712-4410-9247-F632EF8182EFQ37308066-F43A8F23-3D61-4165-81D7-AAF1E724DF7DQ37343908-3802D4A1-D3ED-4F3A-8AE9-DED34A28B5D2Q37420916-EBE18C7C-6490-480D-BF7E-DD730C86C718Q37617591-979392AA-F1C2-4755-8704-540116AAC08BQ38000562-4B9C9691-957D-4957-9EA9-1F8F0B1E9EB3Q38093420-ACCF9D6D-A84C-409E-AA2A-18FAA0141437Q38102665-38963F1F-7C58-41C0-A074-F202A9B9AA58Q46280855-712BF7B5-4DA7-4F4A-AFC5-E2EE813CC3A5Q46554951-838A5472-D91B-4786-AA14-89D5A3F06E6BQ48632087-9244C8A6-1E01-4EEA-BA91-FA24178E2FFA
P2860
Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Effects of BAY 41-2272, a solu ...... reactivity in the ovine fetus.
@en
Effects of BAY 41-2272, a solu ...... reactivity in the ovine fetus.
@nl
type
label
Effects of BAY 41-2272, a solu ...... reactivity in the ovine fetus.
@en
Effects of BAY 41-2272, a solu ...... reactivity in the ovine fetus.
@nl
prefLabel
Effects of BAY 41-2272, a solu ...... reactivity in the ovine fetus.
@en
Effects of BAY 41-2272, a solu ...... reactivity in the ovine fetus.
@nl
P2093
P2860
P1476
Effects of BAY 41-2272, a solu ...... reactivity in the ovine fetus
@en
P2093
Laurent Storme
Steven H Abman
Theresa R Grover
P2860
P304
P356
10.1152/AJPLUNG.00409.2004
P577
2004-12-17T00:00:00Z